Ticagrelor Market: Information by Dosage (Mg) (90 MG and 60 MG), Route of Administration (Oral and Nasogastric Tube), Application (Acute Coronary Syndrome and Heart Surgeries (Angioplasty, Stent Placement and Coronary Artery Bypass Graft)) End User (Hospitals and Clinics and Ambulatory Centers) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2027
ID: MRFR/Pharma/0324-CR | July 2019 | Region: Global | 101 Pages
1 Report Prologue
2 Introduction
2.1 Definition 14
2.2 Scope of the Study 14
2.3 Research Objective 14
2.4 Assumptions & Limitations 14
2.4.1 Assumptions 14
2.4.2 Limitations 14
2.4.3 Market Structure 14
3 Research Methodology
3.1 Primary Research Methodology 16
3.2 Secondary Research Methodology 18
3.3 Market Size Estimation 19
3.4 Forecast Model 19
4 Market Dynamics
4.1 Drivers 21
4.1.1 Rising Cardiovascular Disorders 21
4.1.2 Increasing Geriatric Population 22
4.2 Restraints 22
4.2.1 High Bleeding Complications 22
4.3 Opportunities 22
4.3.1 Exploring New Applications 22
5 Market Factor Analysis
5.1 Porter’s Five Forces Model 24
5.1.1 Bargaining Power of Suppliers 24
5.1.2 Bargaining Power of Buyers 25
5.1.3 Threat of New Entrants 25
5.1.4 Threat of Substitutes 25
5.1.5 Intensity of Rivalry 25
5.2 Value Chain Analysis 26
5.2.1 R&D 26
5.2.2 Manufacturing 26
5.2.3 Distribution & Sales 26
5.2.4 Post-Sales Monitoring 26
5.3 Demand & Supply: Gap Analysis 27
5.4 Pricing Analysis 27
5.5 Investment Opportunities 27
5.6 Macroeconomic Indicators 27
5.7 Pipeline Analysis 28
6 The Global Ticagrelor Market, by Dosage (Mg)
6.1 Introduction 30
6.2 90 MG 31
6.3 60 MG 31
7 The Ticagrelor Market, by Route of Administration
7.1 Introduction 33
7.2 Oral 34
7.3 Nasogastric Tube 34
8 The Ticagrelor Market, by Application
8.1 Introduction 36
8.2 Acute Coronary Syndrome 37
8.3 Heart Surgeries 37
8.3.1 Angioplasty 38
8.3.2 Stent Placement 38
8.3.3 Coronary Artery Bypass Graft 39
9 The Ticagrelor Market, by End User
9.1 Introduction 41
9.2 Hospitals and Clinics 42
9.3 Ambulatory Centers 42
10 The Global Ticagrelor Market, by Region
10.1 Introduction 44
10.2 Americas 46
The Ticagrelor Market, by Route of Administration
The Ticagrelor Market, by Application
The Ticagrelor Market, by End User
10.2.1 North America 48
The Ticagrelor Market, by Route of Administration
The Ticagrelor Market, by Application
The Ticagrelor Market, by End User
10.2.1.1 US 50
The Ticagrelor Market, by Route of Administration
The Ticagrelor Market, by Application
The Ticagrelor Market, by End User
10.2.1.2 Canada 52
The Ticagrelor Market, by Route of Administration
The Ticagrelor Market, by Application
The Ticagrelor Market, by End User
10.2.2 South America 54
The Ticagrelor Market, by Route of Administration
The Ticagrelor Market, by Application
The Ticagrelor Market, by End User
10.3 Europe 56
The Ticagrelor Market, by Route of Administration
The Ticagrelor Market, by Application
The Ticagrelor Market, by End User
10.3.1 Western Europe 58
The Ticagrelor Market, by Route of Administration
The Ticagrelor Market, by Application
The Ticagrelor Market, by End User
10.3.1.1 Germany 60
The Ticagrelor Market, by Route of Administration
The Ticagrelor Market, by Application
The Ticagrelor Market, by End User
10.3.1.2 UK 62
The Ticagrelor Market, by Route of Administration
The Ticagrelor Market, by Application
The Ticagrelor Market, by End User
10.3.1.3 France 63
The Ticagrelor Market, by Route of Administration
The Ticagrelor Market, by Application
The Ticagrelor Market, by End User
10.3.1.4 Italy 65
The Ticagrelor Market, by Route of Administration
The Ticagrelor Market, by Application
The Ticagrelor Market, by End User
10.3.1.5 Spain 67
The Ticagrelor Market, by Route of Administration
The Ticagrelor Market, by Application
The Ticagrelor Market, by End User
10.3.1.6 Rest of Western Europe 68
The Ticagrelor Market, by Route of Administration
The Ticagrelor Market, by Application
The Ticagrelor Market, by End User
10.3.2 Eastern Europe 70
The Ticagrelor Market, by Route of Administration
The Ticagrelor Market, by Application
The Ticagrelor Market, by End User
10.4 Asia-Pacific 72
The Ticagrelor Market, by Route of Administration
The Ticagrelor Market, by Application
The Ticagrelor Market, by End User
10.4.1 Japan 74
The Ticagrelor Market, by Route of Administration
The Ticagrelor Market, by Application
The Ticagrelor Market, by End User
10.4.2 China 76
The Ticagrelor Market, by Route of Administration
The Ticagrelor Market, by Application
The Ticagrelor Market, by End User
10.4.3 India 77
The Ticagrelor Market, by Route of Administration
The Ticagrelor Market, by Application
The Ticagrelor Market, by End User
10.4.4 Australia 79
The Ticagrelor Market, by Route of Administration
The Ticagrelor Market, by Application
The Ticagrelor Market, by End User
10.4.5 South Korea 81
The Ticagrelor Market, by Route of Administration
The Ticagrelor Market, by Application
The Ticagrelor Market, by End User
10.4.6 Rest of Asia-Pacific 82
The Ticagrelor Market, by Route of Administration
The Ticagrelor Market, by Application
The Ticagrelor Market, by End User
10.5 Rest of the World 85
The Ticagrelor Market, by Route of Administration
The Ticagrelor Market, by Application
The Ticagrelor Market, by End User
10.5.1 Middle East 87
The Ticagrelor Market, by Route of Administration
The Ticagrelor Market, by Application
The Ticagrelor Market, by End User
10.5.2 Africa 89
The Ticagrelor Market, by Route of Administration
The Ticagrelor Market, by Application
The Ticagrelor Market, by End User
10.5.3 Other Countries 90
The Ticagrelor Market, by Route of Administration
The Ticagrelor Market, by Application
The Ticagrelor Market, by End User
11 Company Landscape
11.1 Introduction 94
12 Company Profiles
12.1 AstraZeneca, PLC 96
12.1.1 Company Overview 96
12.1.2 Financial Overview 96
12.1.3 Products Offering 97
12.1.4 Key Developments 97
12.1.5 SWOT Analysis 97
12.1.6 Key Strategy 97
13 Appendix
13.1 Discussion Blue Print 99
13.2 References 100
14 List of Tables
TABLE 1 PRIMARY INTERVIEWS 17
TABLE 2 PIPELINE PRODUCTS 28
TABLE 3 GLOBAL TICAGRELOR MARKET, BY DOSAGE (MG) 2020-2027 (USD MILLION) 30
TABLE 4 GLOBAL TICAGRELOR MARKET FOR 90 MG, BY REGION, 2020–2027 (USD MILLION) 31
TABLE 5 GLOBAL TICAGRELOR MARKET FOR 60 MG, BY REGION, 2020–2027 (USD MILLION) 31
TABLE 6 GLOBAL TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2020-2027 (USD MILLION) 33
TABLE 7 GLOBAL TICAGRELOR MARKET FOR ORAL, BY REGION, 2020–2027 (USD MILLION) 34
TABLE 8 GLOBAL TICAGRELOR MARKET FOR NASOGASTRIC TUBE, BY REGION, 2020–2027 (USD MILLION) 34
TABLE 9 GLOBAL TICAGRELOR MARKET, BY APPLICATION 2020-2027 (USD MILLION) 36
TABLE 10 GLOBAL TICAGRELOR MARKET FOR ACUTE CORONARY SYNDROME, BY REGION, 2020–2027 (USD MILLION) 37
TABLE 11 GLOBAL TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2020-2027 (USD MILLION) 37
TABLE 12 GLOBAL TICAGRELOR MARKET FOR HEART SURGERIES, BY REGION 2020-2027 (USD MILLION) 38
TABLE 13 GLOBAL TICAGRELOR MARKET FOR ANGIOPLASTY, BY REGION, 2020–2027 (USD MILLION) 38
TABLE 14 GLOBAL TICAGRELOR MARKET FOR STENT PLACEMENT, BY REGION, 2020–2027 (USD MILLION) 38
TABLE 15 GLOBAL TICAGRELOR MARKET FOR CORONARY ARTERY BYPASS GRAFT-, BY REGION, 2020–2027 (USD MILLION) 39
TABLE 16 GLOBAL TICAGRELOR MARKET, BY END-USER 2020-2027 (USD MILLION) 41
TABLE 17 GLOBAL TICAGRELOR MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2020–2027 (USD MILLION) 42
TABLE 18 GLOBAL TICAGRELOR MARKET FOR AMBULATORY CENTERS, BY REGION, 2020–2027 (USD MILLION) 42
TABLE 19 GLOBAL TICAGRELOR MARKET, BY REGION 2020-2027 (USD MILLION) 45
TABLE 20 AMERICAS TICAGRELOR MARKET, BY REGION 2020-2027 (USD MILLION) 46
TABLE 21 AMERICAS TICAGRELOR MARKET, BY DOSAGE (MG) 2020-2027 (USD MILLION) 46
TABLE 22 AMERICAS TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2020-2027 (USD MILLION) 47
TABLE 23 AMERICAS TICAGRELOR MARKET, BY APPLICATION 2020-2027 (USD MILLION) 47
TABLE 24 AMERICAS TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2020-2027 (USD MILLION) 47
TABLE 25 AMERICAS TICAGRELOR MARKET, BY END-USER 2020-2027 (USD MILLION) 48
TABLE 26 NORTH AMERICA TICAGRELOR MARKET, BY COUNTRY 2020-2027 (USD MILLION) 48
TABLE 27 NORTH AMERICA TICAGRELOR MARKET, BY DOSAGE (MG) 2020-2027 (USD MILLION) 49
TABLE 28 NORTH AMERICA TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2020-2027 (USD MILLION) 49
TABLE 29 NORTH AMERICA TICAGRELOR MARKET, BY APPLICATION 2020-2027 (USD MILLION) 49
TABLE 30 NORTH AMERICA TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2020-2027 (USD MILLION) 49
TABLE 31 NORTH AMERICA TICAGRELOR MARKET, BY END-USER 2020-2027 (USD MILLION) 50
TABLE 32 US TICAGRELOR MARKET, BY DOSAGE (MG) 2020-2027 (USD MILLION) 50
TABLE 33 US TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2020-2027 (USD MILLION) 50
TABLE 34 US TICAGRELOR MARKET, BY APPLICATION 2020-2027 (USD MILLION) 51
TABLE 35 US TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2020-2027 (USD MILLION) 51
TABLE 36 US TICAGRELOR MARKET, BY END-USER 2020-2027 (USD MILLION) 51
TABLE 37 CANADA TICAGRELOR MARKET, BY DOSAGE (MG) 2020-2027 (USD MILLION) 52
TABLE 38 CANADA TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2020-2027 (USD MILLION) 52
TABLE 39 CANADA TICAGRELOR MARKET, BY APPLICATION 2020-2027 (USD MILLION) 52
TABLE 40 CANADA TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2020-2027 (USD MILLION) 53
TABLE 41 CANADA TICAGRELOR MARKET, BY END-USER 2020-2027 (USD MILLION) 53
TABLE 42 SOUTH AMERICA TICAGRELOR MARKET, BY DOSAGE (MG) 2020-2027 (USD MILLION) 54
TABLE 43 SOUTH AMERICA TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2020-2027 (USD MILLION) 54
TABLE 44 SOUTH AMERICA TICAGRELOR MARKET, BY APPLICATION 2020-2027 (USD MILLION) 54
TABLE 45 SOUTH AMERICA TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2020-2027 (USD MILLION) 55
TABLE 46 SOUTH AMERICA TICAGRELOR MARKET, BY END-USER 2020-2027 (USD MILLION) 55
TABLE 47 EUROPE TICAGRELOR MARKET, BY REGION 2020-2027 (USD MILLION) 56
TABLE 48 EUROPE TICAGRELOR MARKET, BY DOSAGE (MG) 2020-2027 (USD MILLION) 56
TABLE 49 EUROPE TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2020-2027 (USD MILLION) 57
TABLE 50 EUROPE TICAGRELOR MARKET, BY APPLICATION 2020-2027 (USD MILLION) 57
TABLE 51 EUROPE TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2020-2027 (USD MILLION) 57
TABLE 52 EUROPE TICAGRELOR MARKET, BY END-USER 2020-2027 (USD MILLION) 58
TABLE 53 WESTERN EUROPE TICAGRELOR MARKET, BY COUNTRY 2020-2027 (USD MILLION) 58
TABLE 54 WESTERN EUROPE TICAGRELOR MARKET, BY DOSAGE (MG) 2020-2027 (USD MILLION) 59
TABLE 55 WESTERN EUROPE TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2020-2027 (USD MILLION) 59
TABLE 56 WESTERN EUROPE TICAGRELOR MARKET, BY APPLICATION 2020-2027 (USD MILLION) 59
TABLE 57 WESTERN EUROPE TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2020-2027 (USD MILLION) 59
TABLE 58 WESTERN EUROPE TICAGRELOR MARKET, BY END-USER 2020-2027 (USD MILLION) 60
TABLE 59 GERMANY TICAGRELOR MARKET, BY DOSAGE (MG) 2020-2027 (USD MILLION) 60
TABLE 60 GERMANY TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2020-2027 (USD MILLION) 60
TABLE 61 GERMANY TICAGRELOR MARKET, BY APPLICATION 2020-2027 (USD MILLION) 61
TABLE 62 GERMANY TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2020-2027 (USD MILLION) 61
TABLE 63 GERMANY TICAGRELOR MARKET, BY END-USER 2020-2027 (USD MILLION) 61
TABLE 64 UK TICAGRELOR MARKET, BY DOSAGE (MG) 2020-2027 (USD MILLION) 62
TABLE 65 UK TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2020-2027 (USD MILLION) 62
TABLE 66 UK TICAGRELOR MARKET, BY APPLICATION 2020-2027 (USD MILLION) 62
TABLE 67 UK TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2020-2027 (USD MILLION) 63
TABLE 68 UK TICAGRELOR MARKET, BY END-USER 2020-2027 (USD MILLION) 63
TABLE 69 FRANCE TICAGRELOR MARKET, BY DOSAGE (MG) 2020-2027 (USD MILLION) 63
TABLE 70 FRANCE TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2020-2027 (USD MILLION) 64
TABLE 71 FRANCE TICAGRELOR MARKET, BY APPLICATION 2020-2027 (USD MILLION) 64
TABLE 72 FRANCE TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2020-2027 (USD MILLION) 64
TABLE 73 FRANCE TICAGRELOR MARKET, BY END-USER 2020-2027 (USD MILLION) 65
TABLE 74 ITALY TICAGRELOR MARKET, BY DOSAGE (MG) 2020-2027 (USD MILLION) 65
TABLE 75 ITALY TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2020-2027 (USD MILLION) 65
TABLE 76 ITALY TICAGRELOR MARKET, BY APPLICATION 2020-2027 (USD MILLION) 66
TABLE 77 ITALY TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2020-2027 (USD MILLION) 66
TABLE 78 ITALY TICAGRELOR MARKET, BY END-USER 2020-2027 (USD MILLION) 66
TABLE 79 SPAIN TICAGRELOR MARKET, BY DOSAGE (MG) 2020-2027 (USD MILLION) 67
TABLE 80 SPAIN TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2020-2027 (USD MILLION) 67
TABLE 81 SPAIN TICAGRELOR MARKET, BY APPLICATION 2020-2027 (USD MILLION) 67
TABLE 82 SPAIN TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2020-2027 (USD MILLION) 68
TABLE 83 SPAIN TICAGRELOR MARKET, BY END-USER 2020-2027 (USD MILLION) 68
TABLE 84 REST OF WESTERN EUROPE TICAGRELOR MARKET, BY DOSAGE (MG) 2020-2027 (USD MILLION) 68
TABLE 85 REST OF WESTERN EUROPE TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2020-2027 (USD MILLION) 69
TABLE 86 REST OF WESTERN EUROPE TICAGRELOR MARKET, BY APPLICATION 2020-2027 (USD MILLION) 69
TABLE 87 REST OF WESTERN EUROPE TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2020-2027 (USD MILLION) 69
TABLE 88 REST OF WESTERN EUROPE TICAGRELOR MARKET, BY END-USER 2020-2027 (USD MILLION) 70
TABLE 89 EASTERN EUROPE TICAGRELOR MARKET, BY DOSAGE (MG) 2020-2027 (USD MILLION) 70
TABLE 90 EASTERN EUROPE TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2020-2027 (USD MILLION) 70
TABLE 91 EASTERN EUROPE TICAGRELOR MARKET, BY APPLICATION 2020-2027 (USD MILLION) 71
TABLE 92 EASTERN EUROPE TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2020-2027 (USD MILLION) 71
TABLE 93 EASTERN EUROPE TICAGRELOR MARKET, BY END-USER 2020-2027 (USD MILLION) 71
TABLE 94 ASIA-PACIFIC TICAGRELOR MARKET, BY COUNTRY 2020-2027 (USD MILLION) 72
TABLE 95 ASIA-PACIFIC TICAGRELOR MARKET, BY DOSAGE (MG) 2020-2027 (USD MILLION) 72
TABLE 96 ASIA-PACIFIC TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2020-2027 (USD MILLION) 73
TABLE 97 ASIA-PACIFIC TICAGRELOR MARKET, BY APPLICATION 2020-2027 (USD MILLION) 73
TABLE 98 ASIA-PACIFIC TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2020-2027 (USD MILLION) 73
TABLE 99 ASIA-PACIFIC TICAGRELOR MARKET, BY END-USER 2020-2027 (USD MILLION) 74
TABLE 100 JAPAN TICAGRELOR MARKET, BY DOSAGE (MG) 2020-2027 (USD MILLION) 74
TABLE 101 JAPAN TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2020-2027 (USD MILLION) 74
TABLE 102 JAPAN TICAGRELOR MARKET, BY APPLICATION 2020-2027 (USD MILLION) 75
TABLE 103 JAPAN TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2020-2027 (USD MILLION) 75
TABLE 104 JAPAN TICAGRELOR MARKET, BY END-USER 2020-2027 (USD MILLION) 75
TABLE 105 CHINA TICAGRELOR MARKET, BY DOSAGE (MG) 2020-2027 (USD MILLION) 76
TABLE 106 CHINA TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2020-2027 (USD MILLION) 76
TABLE 107 CHINA TICAGRELOR MARKET, BY APPLICATION 2020-2027 (USD MILLION) 76
TABLE 108 CHINA TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2020-2027 (USD MILLION) 77
TABLE 109 CHINA TICAGRELOR MARKET, BY END-USER 2020-2027 (USD MILLION) 77
TABLE 110 INDIA TICAGRELOR MARKET, BY DOSAGE (MG) 2020-2027 (USD MILLION) 77
TABLE 111 INDIA TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2020-2027 (USD MILLION) 78
TABLE 112 INDIA TICAGRELOR MARKET, BY APPLICATION 2020-2027 (USD MILLION) 78
TABLE 113 INDIA TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2020-2027 (USD MILLION) 78
TABLE 114 INDIA TICAGRELOR MARKET, BY END-USER 2020-2027 (USD MILLION) 79
TABLE 115 AUSTRALIA TICAGRELOR MARKET, BY DOSAGE (MG) 2020-2027 (USD MILLION) 79
TABLE 116 AUSTRALIA TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2020-2027 (USD MILLION) 79
TABLE 117 AUSTRALIA TICAGRELOR MARKET, BY APPLICATION 2020-2027 (USD MILLION) 80
TABLE 118 AUSTRALIA TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2020-2027 (USD MILLION) 80
TABLE 119 AUSTRALIA TICAGRELOR MARKET, BY END-USER 2020-2027 (USD MILLION) 80
TABLE 120 SOUTH KOREA TICAGRELOR MARKET, BY DOSAGE (MG) 2020-2027 (USD MILLION) 81
TABLE 121 SOUTH KOREA TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2020-2027 (USD MILLION) 81
TABLE 122 SOUTH KOREA TICAGRELOR MARKET, BY APPLICATION 2020-2027 (USD MILLION) 81
TABLE 123 SOUTH KOREA TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2020-2027 (USD MILLION) 82
TABLE 124 SOUTH KOREA TICAGRELOR MARKET, BY END-USER 2020-2027 (USD MILLION) 82
TABLE 125 REST OF ASIA-PACIFIC TICAGRELOR MARKET, BY DOSAGE (MG) 2020-2027 (USD MILLION) 82
TABLE 126 REST OF ASIA-PACIFIC TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2020-2027 (USD MILLION) 83
TABLE 127 REST OF ASIA-PACIFIC TICAGRELOR MARKET, BY APPLICATION 2020-2027 (USD MILLION) 83
TABLE 128 REST OF ASIA-PACIFIC TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2020-2027 (USD MILLION) 83
TABLE 129 REST OF ASIA-PACIFIC TICAGRELOR MARKET, BY END-USER 2020-2027 (USD MILLION) 84
TABLE 130 REST OF THE WORLDTICAGRELOR MARKET, BY REGION 2020-2027 (USD MILLION) 85
TABLE 131 REST OF THE WORLDTICAGRELOR MARKET, BY DOSAGE (MG) 2020-2027 (USD MILLION) 85
TABLE 132 REST OF THE WORLDTICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2020-2027 (USD MILLION) 86
TABLE 133 REST OF THE WORLDTICAGRELOR MARKET, BY APPLICATION 2020-2027 (USD MILLION) 86
TABLE 134 REST OF THE WORLDTICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2020-2027 (USD MILLION) 86
TABLE 135 REST OF THE WORLDTICAGRELOR MARKET, BY END-USER 2020-2027 (USD MILLION) 87
TABLE 136 MIDDLE EAST TICAGRELOR MARKET, BY DOSAGE (MG) 2020-2027 (USD MILLION) 87
TABLE 137 MIDDLE EAST TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2020-2027 (USD MILLION) 87
TABLE 138 MIDDLE EAST TICAGRELOR MARKET, BY APPLICATION 2020-2027 (USD MILLION) 88
TABLE 139 MIDDLE EAST TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2020-2027 (USD MILLION) 88
TABLE 140 MIDDLE EAST TICAGRELOR MARKET, BY END-USER 2020-2027 (USD MILLION) 88
TABLE 141 AFRICA TICAGRELOR MARKET, BY DOSAGE (MG) 2020-2027 (USD MILLION) 89
TABLE 142 AFRICA TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2020-2027 (USD MILLION) 89
TABLE 143 AFRICA TICAGRELOR MARKET, BY APPLICATION 2020-2027 (USD MILLION) 89
TABLE 144 AFRICA TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2020-2027 (USD MILLION) 90
TABLE 145 AFRICA TICAGRELOR MARKET, BY END-USER 2020-2027 (USD MILLION) 90
TABLE 146 OTHER COUNTRIES TICAGRELOR MARKET, BY DOSAGE (MG) 2020-2027 (USD MILLION) 90
TABLE 147 OTHER COUNTRIES TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2020-2027 (USD MILLION) 91
TABLE 148 OTHER COUNTRIES TICAGRELOR MARKET, BY APPLICATION 2020-2027 (USD MILLION) 91
TABLE 149 OTHER COUNTRIES TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2020-2027 (USD MILLION) 91
TABLE 150 OTHER COUNTRIES TICAGRELOR MARKET, BY END-USER 2020-2027 (USD MILLION) 92
15 List of Figures
FIGURE 1 TOP-DOWN & BOTTOM-UP APPROACHES 19
FIGURE 2 MARKET DYNAMICS: GLOBAL TICAGRELOR MARKET 21
FIGURE 3 PORTER’S FIVE FORCES ANALYSIS: GLOBAL TICAGRELOR MARKET 24
FIGURE 4 VALUE CHAIN ANALYSIS OF THE GLOBAL TICAGRELOR MARKET 26
FIGURE 5 GLOBAL TICAGRELOR MARKET, BY DOSAGE (MG) 2020 & 2027 (USD MILLION) 30
FIGURE 6 GLOBAL TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2020 & 2027 (USD MILLION) 33
FIGURE 7 GLOBAL TICAGRELOR MARKET, BY APPLICATION 2020 & 2027 (USD MILLION) 36
FIGURE 8 GLOBAL TICAGRELOR MARKET, FOR HEART SURGERIES BY TYPE 2020 & 2027 (USD MILLION) 37
FIGURE 9 GLOBAL TICAGRELOR MARKET, BY END-USER 2020 & 2027 (USD MILLION) 41
FIGURE 10 GLOBAL TICAGRELOR MARKET, BY REGION 2020 & 2027 (USD MILLION) 45
FIGURE 11 AMERICAS TICAGRELOR MARKET SHARE, BY REGION 2020 (%) 46
FIGURE 12 AMERICAS TICAGRELOR MARKET SHARE, BY COUNTRY 2020 (%) 48
FIGURE 13 EUROPE TICAGRELOR MARKET, BY REGION 2020 (%) 56
FIGURE 14 WESTERN EUROPE TICAGRELOR MARKET, BY COUNTRY 2020 (%) 58
FIGURE 15 ASIA-PACIFIC TICAGRELOR MARKET, BY COUNTRY 2020 (%) 72
FIGURE 16 REST OF THE WORLDTICAGRELOR MARKET, BY REGION 2020(%) 85
Ticagrelor Market
The Ticagrelor Market Size is relied upon to enroll a CAGR of 9.00% and is expected to arrive at USD 2554.39 Million by 2027.
$2554.39 Million
Market Size
9.00%
CAGR
North America
Dominating Region
2020-2027
Forecast Period
Segmentation
Key Players
- AstraZeneca
- Eli Lilly
- Ingelheim
- Alexion
- Roche
- Amgen
- Boehringer
- Pfizer
- Merck
- GSK
- Boehringer
- Amgen
Drivers
- Increasing cardiovascular rate
- Rise in the older population
Ticagrelor Market Overview
The Ticagrelor Market Size is relied upon to enroll a CAGR of 9.00% and is expected to arrive at USD 2554.39 Million by 2027.
You must know that Ticagrelor is an enemy of platelet drugs which diminishes the platelet accumulation and forestalls blood clusters. Ticagrelor works by restricting to the P2Y12 is a one of a kind way and represses the adenosine diphosphate (ADP) motioning by locking the receptor and makes it latent. This frustrates the platelet conglomeration and decreases blood clumps, diminishing the danger of intense coronary condition (ACS).
The expanding cardiovascular rate is, in the end, driving the development of the Ticagrelor Market. They ascend in the more seasoned populace directly affects the market. The more established populace is more inclined to wounds and other medical issue issues, which are the significant drivers moving business sector development. Notwithstanding, Ticagrelor causes draining that can be significant and once in a while prompts demise, compel the development of the Ticagrelor Industry.
The main considerations impacting the development of the Ticagrelor Market incorporate persistent high pool experiencing heart issues, expanding advancement in the item by the organizations, commercialization and further developing business sector access situations, and financing for innovative work by the market players and numerous others. Also, there is an enormous chance in non-industrial nations that is snatched by different market players for extending their quality in the area for Ticagrelor Industry. Due to the major market players, the Ticagrelor Market is expected to grow and develop in the forecasted period.
The Ticagrelor Market is divided into different parts for getting better information about the market development. The market segmentation is done based on type, application, end-user, and region. The Market is segmented as 0 mg Tablet and 60 mg Tablet based on the product type. On the basis of application, the market is segmented into Medical clinic Pharmacies, Retail Pharmacies, and Online Pharmacies. On the basis of end-users, the Ticagrelor Market is segmented into emergency clinics and facilities and wandering focuses. On the basis of region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. This market segmentation gives a better picture of the Ticagrelor Industry and helps the industry's major players take significant market development activities.
COVID 19 Analysis
Since the COVID-19 infection outbreak in December 2019, the illness has spread to pretty much every country all throughout the planet, with the World Health Organization pronouncing it a general wellbeing crisis. The worldwide effects of the Covid sickness 2019 are now beginning to be felt and will fundamentally influence the Ticagrelor Market in 2021. The flare-up of COVID-19 has welcomed impacts on numerous angles, similar to flight undoings; travel boycotts and isolates; eateries shut; all indoor/open-air occasions confined; more than forty nations highly sensitive situation proclaimed; monstrous easing back of the inventory network; financial exchange unpredictability; falling business certainty, developing frenzy among the populace, and vulnerability about future. These situations have a greater impact on the Ticagrelor Industry Growth for the estimated period.
Market Dynamics
Major Drivers of the Market
With expanding patient populace experiencing heart issues, the market is assessed to cultivate during the evaluation time frame. Expanding item improvement by the organizations, subsidizing for innovative work exercises by the significant market players, and further developing business sector access situations are additionally assessed to move the Ticagrelor Industry. Besides, attributable to the presence of a few grounded players, the ticagrelor market is assessed to thrive in the coming years.
Significant Opportunities for the Market
New item dispatches and R&D amongst significant central participants are creating major opportunities in the Ticagrelor Market. These significant opportunities are playing a major role in the Ticagrelor Market development for the forecasted period. With the right approach towards these opportunities, this market could help to the growth of the market quickly and effectively.
Market Restraints
You must know that regardless of the various driving components, a couple of limitations may restrain the market's development. The restraining factors like Incidental effects related to ticagrelor utilize, for example, draining and dyspnea, may debilitate the utilization of ticagrelor. In any case, the improvement of new pharmaceutical compounds containing ticagrelor and rising mindfulness relating to the advantages of brilliant may push the worldwide Ticagrelor Market extension. These restraining factors must be properly handled in order to enhance the market growth in the forecasted period.
Cumulative Growth Analysis
The rising popularity of Ticagrelor among doctors and patients has urged market research to direct a top to bottom examination on the Ticagrelor Industry Growth. In its most recent investigation, it was confirmed that the market's design and revealed insight into the key development elements. It features the development situation and cutthroat scene of the market. Also, it states business methodologies sent by the key ventures working in the worldwide Ticagrelor Industry and finds out the difficulties looked by them over the long run.
Segment Overview
By Types
Based on types, the Market Share is segmented into 90 mg Tablet and 60 mg Tablet. The item section gives data about the piece of the pie of every item and the separate CAGR during the estimated time frame. It spreads out data about the item evaluating boundaries, patterns, and benefits that give inside and out experiences of the Ticagrelor Industry. Moreover, it talks about the most recent item advancements and development on the lookout.
By application
Based on application, the Market is segmented into Medical clinic Pharmacies, Retail Pharmacies, and Online Pharmacies. The application section pieces different utilizations of the item and gives data available offer and development pace of every application fragment. It examines the likely future utilizations of the items and driving and controlling components of every application portion.
By end User
Based on end-user, the Market has been segmented into emergency clinics and facilities and wandering focuses. The medical clinics and facilities fragment represented a market worth of USD 522.03 million out of 2017.
By Region
The worldwide market is segmented on region into the Americas, Europe, Asia-Pacific, and the Middle East, and Africa. The Americas is assessed to rule the worldwide ticagrelor Industry during the estimated time frame.
Regional Analysis
In light of regional analysis, the worldwide Ticagrelor Market Outlook is partitioned into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is assessed to rule the worldwide ticagrelor market during the figure time frame. This market is described to its feasible development in GDP per capita pay and the large rising populace profoundly inclined to degenerative sicknesses and constant diseases, which have caused an expanded skirt of determination and therapeutics. The European market for ticagrelor is relied upon to be the second-biggest during the conjecture time frame. The rising patient populace of strokes and cardiovascular issues, expanding research on antiplatelets, accessibility of cutting edge treatment offices, expanding medical services use, and presentation of cutting edge and incorporated therapy alternatives into the market alongside the presence of good medical care framework is relied upon to help the development of the market around here. Asia-Pacific is assessed to be the quickest developing business sector because of the expanding per capita expendable wages alongside government drives to upgrade the nature of medical care. Also, the rising cases related to cardiovascular illnesses being an essential worry all over the globe.
Competitive Landscape
The major Ticagrelor Market Players are mentioned below:
- AstraZeneca, Eli Lilly
- Ingelheim
- Alexion
- Roche
- Amgen
- Boehringer
- Pfizer
- Merck
- GSK
- Boehringer
- Amgen
Recent Developments
- September 02, 2019, the Strs Ohio (the US), a main worldwide institutional financial backer, reported the securing of another stake in Phase Bio Pharmaceuticals Inc. (the US), a clinical-stage biopharmaceutical organization.
- haseBio centers around the turn of events and commercialization of novel treatments and medications, for example, an inversion specialist for the antiplatelet drug ticagrelor
Report Overview
The Ticagrelor Market Analysis or overviews are as follows:
- Market Overview
- COVID 19 Analysis
- Market dynamics
- Market Trends Segment Overview
- Regional Analysis as per the Market Forecast.
- Market Competitive Landscape
- Developments in Market Value
This report highlights the growth aspects of the Ticagrelor Market Revenue. Along with that, this report also intends to put up the competitive landscape and recent developments on the table to explain this global Atorvastatin API Market position.
Report Scope:
| Report Attribute/Metric | Details |
|---|---|
| Market Size | 2027: USD 2554.39 Million |
| CAGR | 9.00% (2018-2027) |
| Base Year | 2019 |
| Forecast Period | 2020-2027 |
| Historical Data | 2018 |
| Forecast Units | Value (USD Million) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Dosage (Mg), Route of administration, Application, and End user |
| Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Key Vendors | AstraZeneca, PLC. |
| Key Market Opportunities | New product launches and R&D Amongst major key Players |
| Key Market Drivers |
|
Frequently Asked Questions (FAQ) :
Ticagrelor market projected to grow at approximately 9% CAGR during the assessment period (2020-2027).
The valuation of the ticagrelor market is estimated to increase to USD 2554.39 MN by the end of 2027.
Large patient pool suffering from heart problems and increasing product development, commercialization, and improving funding for R&D by the market players are major tailwinds pushing the growth of the ticagrelor market.
North America holds the largest share in the ticagrelor market, followed by Europe and the Asia Pacific, respectively.
AstraZeneca, Eli Lilly, Boehringer, Ingelheim, Pfizer, Amgen, Merck, Roche, GSK, Boehringer, Alexion, and Amgen, are some of the top players operating in the global ticagrelor market.
Company Landscape
Introduction
AstraZeneca is the sole manufacturer of Brilinta (generic: ticagrelor) an “anti-platelet” medication that helps prevent stroke or serious heart problems in patients who have had a heart attack or severe chest pain (angina). The drug works by preventing platelets in the blood from sticking together and forming a blood clot. Brilinta by AstraZeneca was approved by the US Food & Drug Administration (FDA) in July 2011.
The Brilinta 90 mg dosage form by AstraZeneca has been approved in over 100 countries and is included in 12 major acute coronary syndrome (ACS) treatment guidelines globally. Additionally, Brilinta 60mg is approved in over 60 countries for the long-term prevention of death from cardiovascular diseases, heart attack, and stroke for patients with a history of heart attack. AstraZeneca is strongly engaged in growth strategies in order to promote its product across the globe. For instance, in June 2017, the China Food and Drug Administration (CFDA) approved Brilinta 60 mg tablets for patients with a history of heart attack. Subsequently, in July 2017, the Ministry of Human Resources and Social Security agreed to add Brilinta 90 mg to the National Reimbursable Drugs List (NRDL). Similarly, in August 2017, AstraZeneca presented Phase III trial data (PEGASUS-TIMI 54) at the Annual Congress of the European Society of Cardiology (ESC) in Barcelona, Spain. These approvals and presentations are paving a way for the positive growth for Brilinta all over the globe.
The firm has also been focusing on diversifying the applications of Brilinta. For instance, the application of Brilinta in the prevention of vaso-occlusive crises in pediatric patients with sickle cell disease is under investigation. Additionally, the use of Brilinta in patients with type 2 diabetes and coronary artery disease without a previous history of myocardial infarction (MI) or stroke is also been studied. These wide applications of Brilinta are driving the growth of the ticagrelor market.
AstraZeneca has so far been the only provider of ticagrelor and has been accused of prolonging monopoly of the product beyond its legitimate patent life. The firm has been trying to withhold its market presence in the antiplatelet segment by applying for multiple patents. AstraZeneca has filed various lawsuits against firms that have been trying to enter the ticagrelor market by manufacturing generics of Brilinta. For instance, AstraZeneca has filed a lawsuit in the Delhi High Court against the Indian drug maker, Dr. Reddy’s Laboratories to block it from launching generic versions of Brilinta, AstraZeneca’s blockbuster medicine for heart ailments. Additionally, AstraZeneca filed similar lawsuits against Natco Pharmaceuticals and Micro Labs in the early months of 2018 and has blocked both the companies from launching copies of Brilinta.
